STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTGX
  4. [Form 4] Protagonist Therapeutics, Inc Insider Trading Activity

Protagonist Therapeutics (PTGX) CEO sells 100,000 shares after option exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported option exercises and share sales in August 2026 under a Rule 10b5-1 trading plan adopted on January 30, 2026. He exercised stock options for 100,000 shares of common stock at an exercise price of $21.58 per share and sold the resulting 100,000 shares in open-market transactions at weighted average prices of $149.11 on August 10 and $148.52 on August 11. The options exercised were fully vested and were scheduled to expire on October 11, 2026.

Positive

  • None.

Negative

  • None.
Insider PATEL DINESH V PH D
Role President and CEO
Sold 100,000 shs ($14.89M)
Approx. gross sale proceeds $14.89M
Approx. exercise cost $2.16M
Approx. pre-tax spread $12.73M
Type Security Shares Price Value
Exercise Stock Option (right to buy) F1 34,239 $0.00 $0.00
Exercise Common Stock F1 34,239 $21.58 $739K
Sale Common Stock F3 34,239 $148.52 $5.09M
Exercise Stock Option (right to buy) F1 65,761 $0.00 $0.00
Exercise Common Stock F1 65,761 $21.58 $1.42M
Sale Common Stock F2 65,761 $149.11 $9.81M
Holdings After Transaction: Stock Option (right to buy) — 125,000 shares (Direct); Common Stock — 523,478 shares (Direct)
Footnotes (3)
  1. F1. The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.
  2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.41 to $151.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.64 to $151.30. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Shares sold 100,000 shares Total common shares sold in open-market transactions on August 10–11, 2026
Options exercised 100,000 shares Shares underlying stock options exercised at $21.58 per share
Option exercise price $21.58 per share Exercise price of stock options converted into common stock
Weighted average sale price 10 Aug 2026 $149.11 per share Weighted average price for 65,761 shares sold on August 10, 2026
Weighted average sale price 11 Aug 2026 $148.52 per share Weighted average price for 34,239 shares sold on August 11, 2026
10b5-1 plan adoption date January 30, 2026 Date the trading plan governing these transactions was adopted
Option expiration date October 11, 2026 Scheduled expiration date of the exercised stock options
Rule 10b5-1 plan regulatory
"The transactions ... were effected pursuant to a 10b5-1 plan adopted by the reporting person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price per share financial
"The price reported represents the weighted average sale price per share"
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"

FAQ

What did PTGX CEO Dinesh Patel report in this Form 4 filing?
Dinesh V. Patel reported exercising 100,000 stock options at $21.58 per share and selling 100,000 common shares in open-market transactions over two days in August 2026.

How many Protagonist Therapeutics (PTGX) shares did the CEO sell?
The CEO sold 100,000 shares of Protagonist Therapeutics common stock. These shares were acquired from option exercises and then sold in multiple open-market transactions at weighted average prices near $149 per share.

At what prices were the PTGX shares sold by the CEO?
Shares were sold at weighted average prices of $149.11 on August 10, 2026 and $148.52 on August 11, 2026, with individual sale prices ranging roughly from $147 to $151 per share.

What was the exercise price of the PTGX stock options used in these transactions?
The stock options were exercised at an exercise price of $21.58 per share. A total of 100,000 options were exercised, converting into 100,000 shares of Protagonist Therapeutics common stock before being sold.

Were the PTGX CEO’s trades made under a Rule 10b5-1 trading plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on January 30, 2026, covering option exercises and related share sales.

What options did the PTGX CEO exercise in this Form 4?
He exercised fully vested stock options to acquire 100,000 shares of Protagonist Therapeutics common stock at $21.58 per share. The options were scheduled to expire on October 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PATEL DINESH V PH D
(Last)(First)(Middle)
C/O PROTAGONIST THERAPEUTICS, INC.
7707 GATEWAY BLVD., SUITE 140
(Street)
NEWARK CALIFORNIA 94560-1160
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/10/2026M(1)65,761A$21.58589,239D
Common Stock08/10/2026S65,761D$149.11(2)523,478D
Common Stock08/11/2026M(1)34,239A$21.58557,717D
Common Stock08/11/2026S34,239D$148.52(3)523,478D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$21.5808/10/2026M65,761 (1)10/11/2026Common Stock65,761$0.00159,239D
Stock Option (right to buy)$21.5808/11/2026M34,239 (1)10/11/2026Common Stock34,239$0.00125,000D
Explanation of Responses:
1. The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.
2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.41 to $151.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.64 to $151.30. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.08/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR